OIS at AAO 2015

PanOptica

Nov 12, 2015 12:13pm ‐ Nov 12, 2015 12:21pm


Description

PanOptica is completing a first-in-man study of PAN-90806, a novel topically administered VEGF antagonist in patients with newly diagnosed neovascular (wet) AMD. Co-founders Paul Chaney and Dr. Martin Wax lead a small, deeply experienced team and are enabled by the support of Novo Ventures, SV LifeSciences and Third Rock Ventures.

Speaker(s):

You must be logged in and own this session in order to post comments.